PT-141: The First FDA-Approved Peptide for Sexual Health

A Different Mechanism for Sexual Health

Bremelanotide (PT-141, marketed as Vyleesi) represents a fundamentally different approach to sexual health pharmacotherapy. While PDE5 inhibitors (sildenafil, tadalafil) work peripherally on vascular smooth muscle to enhance erectile function, bremelanotide acts centrally — in the brain — through melanocortin receptors to increase sexual desire. This distinction is critical: bremelanotide treats the "wanting," while PDE5 inhibitors treat the "functioning." They address different components of the sexual response cycle (Kingsberg et al., 2019, Obstetrics & Gynecology; PMID: 31135726).

The Melanocortin System

The melanocortin system is a neuroendocrine signaling network involving five receptor subtypes (MC1R through MC5R) and their peptide ligands, primarily alpha-melanocyte-stimulating hormone (alpha-MSH) and related peptides derived from proopiomelanocortin (POMC). This system regulates diverse functions including pigmentation (MC1R), adrenal function (MC2R), energy balance and appetite (MC3R/MC4R), and exocrine function (MC5R).

Sexual desire is regulated in part through MC4R (melanocortin-4 receptor) signaling in the hypothalamus and limbic system. Activation of MC4R in these brain regions promotes sexual arousal and desire through downstream effects on oxytocin and dopaminergic pathways. The discovery that MC4R activation could enhance sexual function was actually serendipitous — researchers studying melanotan II (a tanning peptide) for skin pigmentation noticed that trial participants reported spontaneous sexual arousal as a side effect (Hadley, 2005, Peptides; PMID: 15911072).

From Melanotan II to Bremelanotide

Melanotan II is a nonselective melanocortin agonist that activates multiple MC receptor subtypes, producing effects including skin tanning (MC1R), appetite suppression (MC4R), and sexual arousal (MC4R). However, its nonselective binding raised safety concerns, particularly regarding cardiovascular effects.

Bremelanotide (PT-141) was developed as a more targeted cyclic heptapeptide analogue with preferential activity at MC1R and MC4R. By narrowing the receptor binding profile, developers aimed to retain the sexual function benefits while improving the safety profile. After an initial intranasal formulation was abandoned due to blood pressure concerns, the subcutaneous route was adopted, which demonstrated both efficacy and improved tolerability.

Clinical Trial Data

Bremelanotide's FDA approval was based on two pivotal Phase III trials — RECONNECT-1 and RECONNECT-2 — in premenopausal women with hypoactive sexual desire disorder (HSDD):

• Primary endpoint: Change from baseline in the Female Sexual Function Index (FSFI) desire domain score. Bremelanotide produced statistically significant improvements over placebo in desire (+0.5 points on FSFI desire domain, p < 0.001).
• Secondary endpoint: Change in the Female Sexual Distress Scale (FSDS-DAO). Bremelanotide significantly reduced distress related to low sexual desire.
• Response rates: Approximately 25% of women treated with bremelanotide reported meaningful improvement in desire, compared to 17% with placebo — a modest but statistically significant difference.

The effect sizes are moderate, which is important context for clinical discussions. Bremelanotide is not a "magic switch" for desire — it produces a meaningful improvement in a subset of patients, which is consistent with the complexity of sexual desire as a biopsychosocial phenomenon.

Off-Label Use in Men

While bremelanotide is FDA-approved only for premenopausal women with HSDD, off-label use in men is common in clinical practice. The physiological rationale is sound — MC4R-mediated sexual arousal pathways are present in both sexes. Preliminary studies and clinical experience suggest efficacy for male sexual dysfunction, particularly in cases where PDE5 inhibitors are insufficient or contraindicated, and in men with low desire rather than erectile dysfunction per se.

Typical off-label dosing in men is 1-2 mg subcutaneously, administered 30-60 minutes before anticipated sexual activity. As with the FDA-approved indication, this is on-demand use rather than daily dosing.

Side Effects and Safety

The most common side effects of bremelanotide include:

• Nausea: ~40% incidence, usually mild to moderate, and often diminishes with repeated use. Taking an antiemetic 30 minutes before the injection can help.
• Flushing: ~20%, related to melanocortin-mediated vasodilation.
• Injection site reactions: ~13%, typically mild.
• Headache: ~11%.
• Transient skin darkening: Possible with repeated use due to MC1R activation. This is more common with melanotan II but can occur with bremelanotide, particularly in patients with darker skin types or moles.

Cardiovascular considerations: Bremelanotide can cause a transient, small increase in blood pressure (average 2-3 mmHg systolic) and decrease in heart rate. It is not recommended in patients with uncontrolled hypertension or cardiovascular disease. The FDA label limits use to no more than once every 24 hours and no more than 8 doses per month.

Drug interactions: Bremelanotide should not be used concurrently with naltrexone due to reduced efficacy of both drugs (competitive pharmacodynamic interaction). Caution is advised with medications that slow gastric emptying, as bremelanotide transiently slows GI motility.

Practical Prescribing

Bremelanotide is available as a 1.75 mg/0.3 mL prefilled autoinjector (Vyleesi). Key prescribing considerations:

• Self-administered subcutaneously in the abdomen or thigh
• At least 45 minutes before anticipated sexual activity
• Maximum 1 dose per 24 hours, 8 doses per month
• Set realistic expectations — discuss that approximately 1 in 4 women report meaningful improvement
• Consider a trial of 8 doses before assessing efficacy
• Counsel about nausea and provide antiemetic guidance

The Bigger Picture

Bremelanotide's approval represents an important milestone: recognition that sexual desire is a legitimate medical concern with neurobiological underpinnings that can be therapeutically targeted. Its central mechanism — working through brain circuits that regulate desire rather than peripheral vascular function — opens a conceptually different approach to sexual health pharmacotherapy. While not a panacea, it provides a genuinely novel option for patients whose primary concern is desire rather than physical arousal or function.